The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The plant has a capacity for extraction of 2500 mt of poppy straw and 300 mt poppy gum per year
The product is expected to start contributing meaningfully to the revenue from FY25
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
Subscribe To Our Newsletter & Stay Updated
